Claims
- 1. An anti-microbial composition comprising two components: (a) a quinolone drug that kills bacteria having a gyrase enzyme that is sensitive to said drug; and (b) α-arteether that kills bacteria that are resistant to the quinolone drug by virtue of a mutation in a gyrase gene thereof; the α-arteether and the quinolone drug being present in the composition in respective amounts effective to inhibit development of bacterial resistance to the quinolone drug or α-arteether that would otherwise arise upon contact of a bacterial strain with either of the components singly.
- 2. A composition as claimed in claim 1, wherein the quinolone drug comprises nalidixic acid.
- 3. A composition as claimed in claim 1, wherein the ratio of the α-arteether and the quinolone drug in the composition is about 8:1 to 20:1.
- 4. A composition as claimed in claim 1, wherein the quinolone drug is selected from the group of fluoroquinolones consisting of Ciprofloxacin, Norfloxacin, Levofloxacin, Sparfloxacin, Oxfloxacin and Lomefloxacin.
- 5. A composition as claimed in claim 2, wherein the concentration of nalidixic acid is at least 50 μg/ml.
- 6. A composition as claimed in claim 1, wherein the concentration of α-arteether in the composition is about 2 μg to 500 μg/ml.
- 7. A composition as claimed in claim 1, wherein the concentration of α-arteether in the composition is about 400 μg/ml.
- 8. A composition as claimed in claim 6, wherein the concentration of the quinolone drug in the composition is about 0.5 mg to 500 mg.
- 9. A composition as claimed in claim 1 further comprising a solvent.
- 10. A composition as claimed in claim 9, wherein neutralized sterile vegetable oil is present as the solvent in an amount of at least 1 ml.
- 11. A composition as claimed in claim 1, wherein the said components are DNA gyrase inhibitors with counter-action properties against resistant mutants of each other.
- 12. A composition as claimed in claim 1, wherein the quinolone drug is selected from the group consisting of nalidixic acid and oxalinic acid.
- 13. A composition as claimed in claim 1, wherein the quinolone drug is selected from the group consisting of Lomefloxacin, tosufloxacin and temafloxacin.
- 14. A method for the development of an anti-microbial composition, said method comprising the step of mixing α-arteether and a quinolone drug in respective amounts effective to inhibit development of bacterial resistance to the anti-microbial composition upon contact of the composition with a bacterial strain having a gyrase enzyme.
- 15. A method as claimed in claim 14, wherein the ratio of α-arteether to the quinolone drug in the composition is about 8:1 to 20:1.
- 16. A method as claimed in claim 14, wherein the quinolone drug is nalidixic acid.
- 17. A method as claimed in claim 14, wherein the quinolone drug is selected from the group of fluoroquinolones consisting of Ciprofloxacin, Norfloxacin, Levofloxacin, Sparfloxacin, Oxfloxacin and Lomefloxacin.
- 18. A method as claimed in claim 16, wherein the concentration of nalidixic acid in the composition is at least 50 μg/ml.
- 19. A method as claimed in claim 18, wherein the concentration of α-arteether in the composition is about 2 μg to 50 μg/ml.
- 20. A method as claimed in claim 18, wherein the concentration of α-arteether in the composition is about 400 μg/ml.
- 21. A method as claimed in claim 18, wherein the concentration of the quinolone drug in the composition is about 0.5 mg to 500 mg.
- 22. A method as claimed in claim 14 further comprising including a solvent with the α-arteether and the quinolone drug.
- 23. A method as claimed in claim 22, wherein the solvent is a neutralized sterile vegetable oil.
- 24. A method for treating a bacterial infection in a mammal, wherein the bacterial infection comprises bacteria that are sensitive to a quinolone drug or α-arteether, said bacteria having a gyrase gene that can mutate to cause development of bacterial resistance to the quinolone drug or α-arteether in a later generation of the bacteria, said method comprising:a) providing the composition of claim 1; and b) administering the composition to the mammal in a therapeutically effective amount with inhibition of the development of the bacterial resistance.
- 25. A method for treating a bacterial infection in a mammal, wherein the bacterial infection comprises bacteria that are sensitive to a quinolone drug or α-arteether, said bacteria having a gyrase gene that can mutate to cause development of bacterial resistance to the quinolone drug or α-arteether in a later generation of the bacteria, said method comprising:a) providing the composition of claim 2; and b) administering the composition to the mammal in a therapeutically effective amount with inhibition of the development of the bacterial resistance.
- 26. A method for treating a bacterial infection in a mammal, wherein the bacterial infection comprises bacteria that are sensitive to a quinolone drug or α-arteether, said bacteria having a gyrase gene that can mutate to cause development of bacterial resistance to the quinolone drug or α-arteether in a later generation of the bacteria, said method comprising:a) providing the composition of claim 3; and b) administering the composition to the mammal in a therapeutically effective amount with inhibition of the development of the bacterial resistance.
- 27. A method for treating a bacterial infection in a mammal, wherein the bacterial infection comprises bacteria that are sensitive to a quinolone drug or α-arteether, said bacteria having a gyrase gene that can mutate to cause development of bacterial resistance to the quinolone drug or α-arteether in a later generation of the bacteria, said method comprising:a) providing the composition of claim 6; and b) administering the composition to the mammal in a therapeutically effective amount with inhibition of the development of the bacterial resistance.
- 28. A method for treating a bacterial infection in a mammal, wherein the bacterial infection comprises bacteria that are sensitive to a quinolone drug or α-arteether, said bacteria having a gyrase gene that can mutate to cause development of bacterial resistance to the quinolone drug or α-arteether in a later generation of the bacterial, said method comprising administering to the mammal a quinolone drug and α-arteether in respective amounts effective to inhibit the development of the bacterial resistance.
Priority Claims (1)
Number |
Date |
Country |
Kind |
1967/DEL/98 |
Jul 1998 |
IN |
|
Parent Case Info
This application is a continuation -in-part of application Ser. No 09/179,204 filed Oct. 27, 1998, now U.S. Pat. No. 6,127,405.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
4973590 |
Preiss et al. |
Nov 1990 |
A |
5057501 |
Thornfeldt |
Oct 1991 |
A |
6127405 |
Kumar et al. |
Oct 2000 |
A |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09/179204 |
Oct 1998 |
US |
Child |
09/538439 |
|
US |